Roche, the Swiss pharmaceutical group, is funding a study to test the efficacy of its flu drug Tamiflu in combination with rival GlaxoSmithKline's Relenza, in one of several initiatives to extend further the market for its blockbuster antiviral treatment.
David Reddy, Roche's pandemic taskforce leader, said on Monday his company was supporting research by a French team analysing whether patients could be better treated by using both of the two drugs, which are closely related chemically.
The study, while co-ordinated by an independent research group, marks a rare sign of co-operation between the two companies competing for antiviral sales of the only two drugs recommended for treatment in the current flu pandemic.
您已閱讀42%（722字），剩余58%（984字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。